 Mice, Nude
"Mice, Nude" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
| Descriptor ID |
D008819
|
| MeSH Number(s) |
B01.050.150.900.649.313.992.635.505.500.550.500
|
| Concept/Terms |
Mice, Nude- Mice, Nude
- Athymic Mice
- Mouse, Nude
- Nude Mouse
- Nude Mice
- Mouse, Athymic
- Athymic Mouse
- Mice, Athymic
|
Below are MeSH descriptors whose meaning is more general than "Mice, Nude".
Below are MeSH descriptors whose meaning is more specific than "Mice, Nude".
This graph shows the total number of publications written about "Mice, Nude" by people in this website by year, and whether "Mice, Nude" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 | | 1994 | 1 | 4 | 5 | | 1995 | 0 | 3 | 3 | | 1996 | 0 | 4 | 4 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 3 | 3 | | 1999 | 0 | 4 | 4 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 8 | 8 | | 2003 | 0 | 3 | 3 | | 2004 | 0 | 6 | 6 | | 2005 | 0 | 10 | 10 | | 2006 | 0 | 14 | 14 | | 2007 | 0 | 6 | 6 | | 2008 | 0 | 11 | 11 | | 2009 | 0 | 18 | 18 | | 2010 | 0 | 11 | 11 | | 2011 | 0 | 21 | 21 | | 2012 | 0 | 17 | 17 | | 2013 | 0 | 17 | 17 | | 2014 | 0 | 17 | 17 | | 2015 | 0 | 15 | 15 | | 2016 | 0 | 11 | 11 | | 2017 | 0 | 19 | 19 | | 2018 | 0 | 12 | 12 | | 2019 | 0 | 6 | 6 | | 2020 | 0 | 11 | 11 | | 2021 | 0 | 8 | 8 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mice, Nude" by people in Profiles.
-
Manuel CA, Johnson LK, Pugazhenthi U, Fong DL, Fink M, Habenicht LM, Leszczynski JK, Diana IR, Schurr MJ, Frank DN. Effect of Antimicrobial Prophylaxis on Corynebacterium bovis Infection and the Skin Microbiome of Immunodeficient Mice. Comp Med. 2022 04 01; 72(2):78-89.
-
Kurth I, Yamaguchi N, Andreu-Agullo C, Tian HS, Sridhar S, Takeda S, Gonsalves FC, Loo JM, Barlas A, Manova-Todorova K, Busby R, Bendell JC, Strauss J, Fakih M, McRee AJ, Hendifar AE, Rosen LS, Cercek A, Wasserman R, Szarek M, Spector SL, Raza S, Tavazoie MF, Tavazoie SF. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 10 08; 7(41):eabi7511.
-
Smith BD, Kaufman MD, Wise SC, Ahn YM, Caldwell TM, Leary CB, Lu WP, Tan G, Vogeti L, Vogeti S, Wilky BA, Davis LE, Sharma M, Ruiz-Soto R, Flynn DL. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. Mol Cancer Ther. 2021 11; 20(11):2098-2109.
-
Gartrell J, Mellado-Largarde M, Clay MR, Bahrami A, Sahr NA, Sykes A, Blankenship K, Hoffmann L, Xie J, Cho HP, Twarog N, Connelly M, Yan KK, Yu J, Porter SN, Pruett-Miller SM, Neale G, Tinkle CL, Federico SM, Stewart EA, Shelat AA. SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents. Mol Cancer Ther. 2021 11; 20(11):2151-2165.
-
Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouët-Astrié C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 10; 20(10):2049-2060.
-
Sottnik JL, Vanderlinden L, Joshi M, Chauca-Diaz A, Owens C, Hansel DE, Sempeck C, Ghosh D, Theodorescu D. Androgen Receptor Regulates CD44 Expression in Bladder Cancer. Cancer Res. 2021 06 01; 81(11):2833-2846.
-
Nief C, Morhard R, Chelales E, Adrianzen Alvarez D, Bourla Bs I, Lam CT, Sag AA, Crouch BT, Mueller JL, Katz D, Dewhirst MW, Everitt JI, Ramanujam N. Polymer-assisted intratumoral delivery of ethanol: Preclinical investigation of safety and efficacy in a murine breast cancer model. PLoS One. 2021; 16(1):e0234535.
-
Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clin Cancer Res. 2021 03 15; 27(6):1681-1694.
-
Wallace E, Hendrickson D, Tolli N, Mehaffy C, Peña M, Nick JA, Knabenbaur P, Watkins J, Simpson A, Amin AG, Chatterjee D, Dobos KM, Lahiri R, Adams L, Strong M, Salfinger M, Bradford R, Stedman TT, Riojas MA, Hazbón MH. Culturing Mycobacteria. Methods Mol Biol. 2021; 2314:1-58.
-
Estrada-Bernal A, Le AT, Doak AE, Tirunagaru VG, Silva S, Bull MR, Smaill JB, Patterson AV, Kim C, Liu SV, Doebele RC. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 03 01; 27(5):1463-1475.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|